Shandong Keyuan Pharmaceutical Co. Ltd. A - Asset Resilience Ratio
Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) has an Asset Resilience Ratio of 6.44% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 301281 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how Shandong Keyuan Pharmaceutical Co. Ltd. A's Asset Resilience Ratio has changed over time. See 301281 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shandong Keyuan Pharmaceutical Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Shandong Keyuan Pharmaceutical Co. Ltd. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥103.29 Million | 6.44% |
| Total Liquid Assets | CN¥103.29 Million | 6.44% |
Asset Resilience Insights
- Limited Liquidity: Shandong Keyuan Pharmaceutical Co. Ltd. A maintains only 6.44% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shandong Keyuan Pharmaceutical Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Shandong Keyuan Pharmaceutical Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.48% |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096 |
Drug Manufacturers - General | 1.58% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
Annual Asset Resilience Ratio for Shandong Keyuan Pharmaceutical Co. Ltd. A (2023–2024)
The table below shows the annual Asset Resilience Ratio data for Shandong Keyuan Pharmaceutical Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 16.39% | CN¥254.43 Million ≈ $37.23 Million |
CN¥1.55 Billion ≈ $227.18 Million |
+6.15pp |
| 2023-12-31 | 10.24% | CN¥150.54 Million ≈ $22.03 Million |
CN¥1.47 Billion ≈ $215.10 Million |
-- |
About Shandong Keyuan Pharmaceutical Co. Ltd. A
Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clemastine fumarate; chlorpheniramine maleate; esmo… Read more